Generic Medicine Info
Hypersensitivity to rifabutin and other rifamycins.
Special Precautions
Renal and hepatic impairment. Pregnancy and lactation. Patient Counselling May impart a red-orange colour to the urine, skin and body secretions. Contact lenses, esp soft, may be permanently stained. Monitoring Parameters Monitor CBC w/ differential, platelet counts, and liver enzymes periodically during treatment. Before starting prophylaxis, assess patients to ensure that they do not have active disease caused by pulmonary TB or other mycobacteria.
Adverse Reactions
Rash, GI disturbances, neutropenia, syndrome of polyarthralgia-arthritis at doses >1 g/day, uveitis esp in patients receiving clarithromycin or other macrolides, asymptomatic corneal opacities after long-term use, orange-tan skin pigmentation, flu-like syndrome, hepatitis, leucopenia, epigastric pain, erythema, ageusia.
Potentially Fatal: Clostridium difficile-associated diarrhoea (CDAD).
Drug Interactions
Increased plasma levels w/ clarithromycin (and possibly other macrolides), triazole atifungals (e.g. fluconazole, itraconazole), antivirals (e.g. indinavir, fosamprenavir, ritonavir). May reduce the activity of analgesics, anticoagulants, corticosteroids, ciclosporin, digitalis (although not digoxin), oral hypoglycaemics, narcotics, phenytoin and quinidine. Delayed GI absorption w/ p-aminosalicylic acid. May reduce serum concentration of OC or tacrolimus.
ATC Classification
J04AB04 - rifabutin ; Belongs to the class of antibiotics. Used in the systemic treatment of tuberculosis.
Disclaimer: This information is independently developed by CIMS based on rifabutin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in